Trius Therapeutics Inc., of San Diego, will collaborate with Bayer Pharma AG, of Leverkusen, Germany, to develop and commercialize Trius' lead Phase III antibiotic, torezolid phosphate, in Africa, Asia (excluding North and South Korea), Latin America and the Middle East.